Developmental Research Program
发展研究计划
基本信息
- 批准号:8485829
- 负责人:
- 金额:$ 15.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-18 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdvocateApplication procedureAwardCancer Research ProjectCaringClinicalDataDevelopmentEvolutionFacultyFinancial SupportFundingFutureGrantHumanIncubatorsIndividualInstitutionMalignant neoplasm of ovaryMeasuresPatientsPilot ProjectsPopulation ResearchPrincipal InvestigatorProceduresProcessProgram Research Project GrantsRecommendationResearchResearch PersonnelResearch Project GrantsSpecimenStudy SectionTestingTranslational ResearchUnited States National Institutes of HealthUniversity of Pittsburgh Cancer Instituteanticancer researchbaseflexibilityhigh rewardhigh riskinnovationinterestnext generationpatient populationprogramsresearch and developmentsuccess
项目摘要
The Developmental Research Program of the RPCI-UPCI Ovarian Cancer SPORE is a platform to support innovative, potentially high-risk/high-reward, investigator-initiated projects with the potential for maturation into translational ovarian cancer research projects that will transit basic and/or population research findings into research focused on human clinical specimens/patient populations. Furthermore, the funds of the Developmental Research Program will be leveraged by encouraging the development of the pilot projects into collaborative, multi-investigator, multi-institutional translational research programs, or as replacements for the Individual Research Projects of the RPCI-UPCI Ovarian Cancer SPORE. Therefore, the Developmental Research Program projects are the ultimate measure of the success of a SPORE, and form the base for future translational ovarian cancer research at the individual institutions since they are the springboard for the next generation of R01, P01, Consortium, and SPORE grants. Proposals from faculty with established ovarian cancer research programs, or faculty interested in transitioning to translational ovarian cancer research, will be evaluated by the Executive Committee for scientific merit. The Development Research Program Leaders will convene a NIH format study section and assign NIH R21- type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. The Developmental Research Program will fund three to four projects per year at a funding level of $50,000 per year. Highly promising projects are eligible for an additional year of funding, but in order to maintain maximal flexibility in attracting new innovative projects, no more than one project per year will be a renewal. The unique strengths of the Developmental Research Program lie in its ability to provide significant financial support in a timely manner to high-risk/pilot projects to develop critical preliminary data, provide a flexible mechanism that can respond rapidly to new initiatives or exciting findings through a formal application procedure using the Executive Committee and Internal Advisory Board, or receive even quicker but lesser funds through an ad hoc award from the Discretionary Fund of the RPCI-UPCI Ovarian Cancer SPORE Principal Investigator.
RPCI-UPCI卵巢癌SPORE的发展研究计划是一个平台,支持创新的,潜在的高风险/高回报的,具有成熟为转化卵巢癌研究项目的潜力,将基础和/或人群研究结果转化为关注人类临床标本/患者人群的研究。此外,发展研究计划的资金将通过鼓励试点项目发展为合作,多研究者,多机构的转化研究计划,或作为RPCI-UPCI卵巢癌孢子的个人研究项目的替代品来利用。因此,发展研究计划项目是SPORE成功的最终衡量标准,并形成了各个机构未来转化卵巢癌研究的基础,因为它们是下一代R 01,P01,财团和SPORE赠款的跳板。来自已建立卵巢癌研究计划的教师或有兴趣过渡到转化卵巢癌研究的教师的建议,将由执行委员会评估其科学价值。发展研究项目负责人将召集NIH格式研究部分,并将NIH R21类型的申请分配给两名科学和一名患者倡导评审员。审查结果将汇总在行政核心文件中,并提交给内部咨询委员会,供其提出供资建议。发展研究计划每年将资助三到四个项目,每年的资金水平为50,000美元。非常有前途的项目有资格获得额外一年的资金,但为了保持最大的灵活性,以吸引新的创新项目,每年不超过一个项目将被延长。发展研究计划的独特优势在于它能够及时为高风险/试点项目提供重要的财政支持,以开发关键的初步数据,提供灵活的机制,可以通过使用执行委员会和内部咨询委员会的正式申请程序,快速响应新举措或令人兴奋的发现,或者通过RPCI-UPCI卵巢癌SPORE主要研究者的酌情基金的特别奖励获得更快但更少的资金。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIRSTEN B. MOYSICH其他文献
KIRSTEN B. MOYSICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIRSTEN B. MOYSICH', 18)}}的其他基金
Novel immunological biomarkers ovarian cancer prognosis
卵巢癌预后的新型免疫生物标志物
- 批准号:
8896245 - 财政年份:2015
- 资助金额:
$ 15.76万 - 项目类别:
Myeloid Derived Suppressor Cells in Ovarian Carcinogenesis
卵巢癌发生中的骨髓源性抑制细胞
- 批准号:
8485811 - 财政年份:2013
- 资助金额:
$ 15.76万 - 项目类别: